Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215133 | 1.00 | FFAR1 (0.44) | FFAR1NPC1RAB9ASIRT2KMT2A | |
| SCHEMBL2206301 | 1.00 | FFAR1 (0.44) | FFAR1NPC1RAB9ASIRT2KMT2A | |
| SCHEMBL4568873 | 0.86 | ALOX5 (0.48) | FFAR1KMT2ASMN1; SMN2 | |
| SCHEMBL29818763 | 0.86 | KMT2A (0.58) | KMT2ASMN1; SMN2 | |
| SCHEMBL2207119 | 0.86 | KMT2A (0.58) | KMT2ASMN1; SMN2 | |
| SCHEMBL2206280 | 0.86 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL29818808 | 0.86 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2 | |
| SCHEMBL15150955 | 0.86 | KMT2A (0.46) | KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16030632 | 0.85 | KMT2A (0.56) | KMT2ASMN1; SMN2 | |
| SCHEMBL2204430 | 0.85 | KMT2A (0.45) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | FFAR1 582/4885NPC1 47/4885RAB9A 2120/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | FFAR1 582/4885NPC1 47/4885RAB9A 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.